ArticleJournal of molecular histology2025
Effects of hypervitaminosis C and D on spermatogenesis through CDKN1B modulation in adult male mice: biochemical and immunohistochemical studies.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vitamin D in male reproduction: molecular mechanisms and pharmacological perspectives.Frontiers in pharmacology · 2026Review
- Calcium Channels and Modulators as Potential Therapeutic Targets for Contraceptives and Male Fertility: A Scoping Review.Open access journal of contraception · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe complex biological process of spermatogenesis produces mature spermatozoa within the testicular environment by terminally differentiating male germ precursor cells. Vitamin C (VC) is a potent water-soluble antioxidant. It has a vital antioxidant role, crucial for maintaining tissue formation and functionality by protecting vital macromolecules from oxidative damage. The essential role of vitamin D (VD) in the male reproductive system has been suggested due to the expression of vitamin D receptor (VDR) and Vitamin D-metabolizing enzymes in the testis and spermatozoa.
aimThis study examines the effects of high-dose VC and VD on sperm quality, testosterone levels, and hepatorenal function, focusing on CDKN1B expression during spermatogenesis.
methodsTwenty-seven male mice were divided into three groups (n = 9/group): (1) saline vehicle control, (2) VC treatment (40 mg/kg, or 800 IU/kg), and (3) VD treatment (25 µg/kg, or 1000 IU/kg). For 15 days, intraperitoneal injections were given every day. Histological and immunohistochemical expression of CDKN1B, as well as biochemical investigations, including liver and kidney biomarkers, testosterone, and sperm parameters, were performed on day 16."
resultsHigh-dose vitamin D (VD) treatment significantly reduced sperm count and motility (p < 0.01), alongside a marked decline in testosterone levels (p < 0.01). Hepatorenal toxicity was evident, with significantly elevated liver enzymes (ALT & AST) and kidney biomarkers (Creatinine & Urea) (p < 0.05), with a significant reduction in testis length and weight (p < 0.05). In contrast, vitamin C (VC) treatment showed non-significant improvements in sperm motility and testosterone levels, with no adverse hepatorenal effects. Immunohistochemical analysis revealed elevated CDKN1B expression in VD-treated spermatocytes, indicative of cell cycle arrest during spermatogenesis. In contrast, VC downregulated CDKN1B, with no significant reduction in testis weight or length.
conclusionThrough hepatorenal toxicity, hormonal suppression, and spermatogenesis disruption mediated by CDKN1B, hypervitaminosis D reduces male fertility. VC, on the other hand, has beneficial antioxidant properties without any adverse effects. These results support cautious VD monitoring and draw attention to the dangers of excessive VD supplementation, especially in clinical settings that employ CYP-inducing drugs. VC might be a safe supplemental treatment for infertility brought on by oxidative stress.
Indexed as
Identifiers
40542892What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.